Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy

$267m Deal Expands Biotech’s Research

 
• By Andrew McConaghie
  
Brain scan
After starting with liver diseases, MiNA will now look to target neurodegenerative diseases
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip